 Alprostadil
"Alprostadil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent vasodilator agent that increases peripheral blood flow.
| Descriptor ID |
D000527
|
| MeSH Number(s) |
D10.251.355.255.550.250.050 D10.251.355.325.050 D23.469.050.175.725.780.050
|
| Concept/Terms |
Alprostadil- Alprostadil
- Prostaglandin E1alpha
- PGE1alpha
- Prostaglandin E1
- Lipo-PGE1
- Lipo PGE1
- PGE1
Edex- Edex
- Viridal
- Prostavasin
- Schwarz Brand of Alprostadil
- Allphar Brand of Alprostadil
- Hoyer Brand of Alprostadil
Prostin VR- Prostin VR
- Minprog
- Paladin Brand of Alprostadil
- Pharmacia Brand 1 of Alprostadil
- AstraZeneca Brand of Alprostadil
- Vivus Brand of Alprostadil
- Abbott Brand of Alprostadil
- Astra Brand of Alprostadil
- Janssen Brand of Alprostadil
- Prostine VR
Vasaprostan- Vasaprostan
- Schwarz Pharma Brand of Alprostadil
Caverject- Caverject
- Sugiran
- Pharmacia Brand 2 of Alprostadil
|
Below are MeSH descriptors whose meaning is more general than "Alprostadil".
Below are MeSH descriptors whose meaning is more specific than "Alprostadil".
This graph shows the total number of publications written about "Alprostadil" by people in this website by year, and whether "Alprostadil" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1983 | 0 | 1 | 1 | | 1985 | 0 | 1 | 1 | | 1990 | 1 | 0 | 1 | | 1993 | 0 | 1 | 1 | | 1999 | 2 | 0 | 2 | | 2005 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Alprostadil" by people in Profiles.
-
Copel L, Katz R, Blachar A, Sosna J, Sheiman RG. Clinical and duplex US assessment of effects of sildenafil on cavernosal arteries of the penis: comparison with intracavernosal injection of vasoactive agents--initial experience. Radiology. 2005 Dec; 237(3):986-91.
-
O'Sullivan BP, Linden MD, Frelinger AL, Barnard MR, Spencer-Manzon M, Morris JE, Salem RO, Laposata M, Michelson AD. Platelet activation in cystic fibrosis. Blood. 2005 Jun 15; 105(12):4635-41.
-
Abraham E, Baughman R, Fletcher E, Heard S, Lamberti J, Levy H, Nelson L, Rumbak M, Steingrub J, Taylor J, Park YC, Hynds JM, Freitag J. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med. 1999 Aug; 27(8):1478-85.
-
Heard SO, Longtine K, Toth I, Puyana JC, Potenza B, Smyrnios N. The influence of liposome-encapsulated prostaglandin E1 on hydrogen peroxide concentrations in the exhaled breath of patients with the acute respiratory distress syndrome. Anesth Analg. 1999 Aug; 89(2):353-7.
-
Zurier RB. Fatty acids, inflammation and immune responses. Prostaglandins Leukot Essent Fatty Acids. 1993 Jan; 48(1):57-62.
-
Clive DM, Stoff JS, Cardi M, MacIntyre DE, Brown RS, Salzman EW. Evidence that circulating 6keto prostaglandin E1 causes the platelet defect of Bartter's syndrome. Prostaglandins Leukot Essent Fatty Acids. 1990 Dec; 41(4):251-8.
-
Whittum J, Goldschneider I, Greiner D, Zurier R. Developmental abnormalities of terminal deoxynucleotidyl transferase positive bone marrow cells and thymocytes in New Zealand mice: effects of prostaglandin E1. J Immunol. 1985 Jul; 135(1):272-80.
-
Morain WD, Pettit RJ, Rothkopf DM, Coombs DW. Augmentation of surviving flap area by intraarterial vasodilators administered through implantable pumps. Ann Plast Surg. 1983 Jul; 11(1):46-52.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|